Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis

Ozanimod has recently received US Food and Drug Administration approval for moderate-to-severe ulcerative colitis. Treatment of acute severe colitis remains a clinical challenge, and although many patients respond to cyclosporine therapy, there remains a relative paucity of maintenance options. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Nathaniel A., Dalal, Sushila R., Choi, David, Rubin, David T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302285/
https://www.ncbi.nlm.nih.gov/pubmed/35919406
http://dx.doi.org/10.14309/crj.0000000000000832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302285/
https://www.ncbi.nlm.nih.gov/pubmed/35919406
http://dx.doi.org/10.14309/crj.0000000000000832

Ejemplares similares